HighTower Advisors’s Biohaven BHVN Stock Holding History

HighTower Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,870	Closed	-$219K	–	3769
2024 Q4	$219K	Buy	5,870 +335	+6%	+$15.6K	﹤0.01%	3131
2024 Q3	$276K	Buy	+5,535	New	+$215K	﹤0.01%	2870
2024 Q2	–	Sell	-6,004	Closed	-$327K	–	3704
2024 Q1	$327K	Buy	6,004 +687	+13%	+$34K	﹤0.01%	2611
2023 Q4	$227K	Buy	+5,317	New	+$165K	﹤0.01%	2933

Other funds holding BHVN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

HighTower Advisors's BHVN Position: Q1 2025 in Review

HighTower Advisors sold out of Biohaven (BHVN) in Q1 2025, closing a stake of 5,870 shares — an estimated $219K sold.

HighTower Advisors first reported a position in BHVN in Q4 2023 and held it in 4 quarters. The position peaked at $327K in Q1 2024. 266 funds tracked by Wall St. Rank hold BHVN as of Q1 2025.

HighTower Advisors reported no remaining Biohaven position as of Q1 2025 after selling out during the quarter.
HighTower Advisors sold 5,870 Biohaven shares in Q1 2025, an estimated $219K.
HighTower Advisors first reported a position in Biohaven in Q4 2023 and held it in 4 quarters.
HighTower Advisors's Biohaven position peaked at $327K in Q1 2024.
266 funds tracked by Wall St. Rank held Biohaven as of Q1 2025.

Based on HighTower Advisors's 13F filing for Q1 2025, filed 13 May 2025.